Memorial Sloan Kettering Cancer Center (MSK) is a free-standing NCI-designated Comprehensive Cancer Center dedicated to improving the standards of cancer treatment, prevention and control. MSK?s research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Structural and Chemical Biology); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Population Science Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators. MSK seeks to encourage the application of scientific discoveries in a way that advances the prevention, detection, diagnosis, and treatment of the many forms of cancer that are relevant to the population in our catchment area. Scientific work in the 10 research programs depends on services provided by 26 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 20 of these core facilities. Over the next five years, MSK will continue to enhance its clinical and research facilities and its research and training programs in emerging research areas. Support is requested to provide developmental funding for the support of newly recruited investigators in computational biology, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance

Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084809
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Park, Jae H; Romero, F Andres; Taur, Ying et al. (2018) Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 67:533-540
Berhe, Simon; Danzer, Enrico; Meyers, Paul et al. (2018) Unusual abdominal metastases in osteosarcoma. J Pediatr Surg Case Rep 28:13-16
Dy, Benzon M; Katabi, Nora; Boucai, Laura et al. (2018) Follicular Carcinoma Masquerading as a Hot Nodule in a Pediatric Patient. Am Surg 84:1117-1119
Pareja, Fresia; Brandes, Alissa H; Basili, Thais et al. (2018) Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun 9:3533
Yeoh, Cindy; Fischer, Gregory; Tollinche, Luis (2018) Arrest Under Anesthesia - What was the Culprit? A Case Report. EC anaesth 4:372-375
Lendvai, Nikoletta; Tsakos, Ioanna; Devlin, Sean M et al. (2018) Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leuk Lymphoma 59:1981-1985
Bombard, Yvonne; Clausen, Marc; Mighton, Chloe et al. (2018) The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. Eur J Hum Genet 26:984-995
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Staehler, M; Motzer, R J; George, D J et al. (2018) Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 29:2098-2104
Cybulska, Paulina; Goss, Cheryl; Tew, William P et al. (2018) Corrigendum to ""Indications for and complications of transfusion and the management of gynecologic malignancies"" [Gynecol. Oncol. 146 (2017) 416-426]. Gynecol Oncol 148:235

Showing the most recent 10 out of 8799 publications